Shimizu, Toshimasa
Kawashiri, Shin-ya
Morimoto, Shimpei
Kawazoe, Yurika
Kuroda, Shohei
Kawasaki, Rina
Ito, Yasuko
Kiya, Rieko
Sato, Shuntaro
Yamamoto, Hiroshi
Kawakami, Atsushi
Funding for this research was provided by:
Gilead Sciences
Article History
Received: 24 August 2022
Accepted: 16 February 2023
First Online: 3 March 2023
Declarations
:
: The study protocol was approved by the certified review board of Nagasaki University. The reference number is CRB20-026. Written informed consent will be provided by the patients before enrollment.
: Results obtained in this trial will be published in an international journal and may be presented at international scientific meetings. This information will be included in the patient consent form.
: AK received research funding from ONO Pharmaceutical Co., Sanofi K.K., Asahi Kasei Pharma Corporation, Taisho Toyama Pharmaceutical Co., Teijin Pharma Co., Chugai Pharmaceutical Co., MSD Co., Kyowa Hakko Kirin Co., Boehringer Ingelheim Japan, AbbVie GK, Astellas Pharma Inc., Eli Lilly Japan, Daiichi Sankyo Co., Takeda Pharmaceutical Co., Mitsubishi Tanabe Pharma Co., Bristol-Myers Squibb, Alexion GK, Eisai Co., Celltrion Healthcare Co., AYUMI Pharmaceutical Co., Neopharma Japan Co., Novartis Pharma K.K., and Gilead Sciences, Inc. The other authors declare that they have no competing interests.